Herpangina

Herpangina is represented in the provided sources as a named viral condition with historical scholarly references, including publications indexed in 1951, 1953, and 2005 ^[1][2][3]. The only clinical characterization available in the source set links it to enterovirus-associated disease and describes it as a mucosal feature within that syndrome rather than providing a dedicated standalone definition ^[4]. Source-backed detail on etiology, incubation, or formal case definition is not yet available in the supplied material ^[1][2][3][4].

The source material associates herpangina with febrile presentations and mucosal involvement, specifically oral ulcerations in the setting of enterovirus-associated hand, foot, and mouth disease ^[4]. No additional symptom sequence, duration, anatomic distribution beyond the oral mucosa, or complication profile for herpangina alone is stated in the supplied snippets ^[4]. The broader enterovirus review notes that most HFMD cases resolve without consequence, although a subset can progress to severe neurological and cardiopulmonary complications; this severity statement applies to HFMD in general and not specifically to isolated herpangina ^[4]. Source-backed detail on recurrence, hospitalization, or age-specific clinical course for herpangina itself is not yet available ^[4].

The available evidence places the related enterovirus syndrome in a worldwide public-health context and states that it commonly occurs in children five years of age or younger ^[4]. The same review reports that the impact of enterovirus-associated HFMD is increasing globally and highlights the need for a global enterovirus surveillance network ^[4]. However, the supplied sources do not provide herpangina-specific incidence, regional distribution, seasonality, outbreak settings, or burden estimates ^[1][2][3][4]. The scholarly metadata shows that herpangina has been the subject of medical publication for decades, but no epidemiologic data are included in those records ^[1][2][3].

No herpangina-specific transmission route is stated in the supplied material ^[1][2][3][4]. The only directly relevant source information is that herpangina appears as a mucosal manifestation in enterovirus-associated HFMD, a condition attributed to enteroviruses ^[4]. Beyond that association, source-backed detail on person-to-person spread, respiratory, fecal-oral, or other exposure mechanisms is not yet available in the provided snippets ^[4].

The clearest source-backed risk group in the provided material is children five years of age or younger, as stated for enterovirus-associated HFMD in which mucosal herpangina is a typical manifestation ^[4]. No additional herpangina-specific high-risk populations are identified in the snippets ^[1][2][3][4].

The strongest prevention-related statement in the source set is the review’s emphasis that developing efficacious vaccines has become a priority for preventing enterovirus infections in the absence of adequate treatment ^[4]. The same source also calls for a vigilant global surveillance system for enterovirus infections ^[4]. No herpangina-specific nonpharmaceutical prevention measures, isolation guidance, or vaccine recommendations are provided in the supplied snippets ^[1][2][3][4].

In surveillance terms, herpangina should be read cautiously as an oral-mucosal feature within a broader enterovirus disease spectrum rather than as a fully characterized standalone entity in the supplied material ^[4]. The source set supports its relevance to monitoring enterovirus activity, especially in young children, but does not provide a formal surveillance case definition for herpangina ^[4]. Because the evidence boundary is sparse, source-backed detail on trend interpretation, thresholds, or reporting practices is not yet available ^[1][2][3][4].

1. 1 Herpangina. Treatment of Oral Diseases. 2005. doi: 10.1055/b-0034-55826. DOI: https://doi.org/10.1055/b-0034-55826
2. 2 Herpangina. Archiv f�r die gesamte Virusforschung. 1953. doi: 10.1007/bf01242417. DOI: https://doi.org/10.1007/bf01242417
3. 3 Herpangina. New England Journal of Medicine. 1951. doi: 10.1056/nejm195108232450801. DOI: https://doi.org/10.1056/nejm195108232450801
4. 4 Huang CY et al. A review of enterovirus-associated hand-foot and mouth disease: preventive strategies and the need for a global enterovirus surveillance network. Pathog Glob Health. 2024 Oct-Dec. PMID: 39229797. doi: 10.1080/20477724.2024.2400424. PubMed: https://pubmed.ncbi.nlm.nih.gov/39229797/
5. 5 Chapple ILC et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018 Jun. PMID: 29926944. doi: 10.1002/JPER.17-0719. PubMed: https://pubmed.ncbi.nlm.nih.gov/29926944/
6. 6 Chapple ILC et al. Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Clin Periodontol. 2018 Jun. PMID: 29926499. doi: 10.1111/jcpe.12940. PubMed: https://pubmed.ncbi.nlm.nih.gov/29926499/

ICD-10

ICD-11

Total cases

1.2M

Peak month

2023-07

Coverage

1 reporting countries · 2012-09-15 → 2026-06-20